Plutonium is one of the most hazardous substances that can get inside the human body, though the reason is not what most people assume. Its danger comes almost entirely from its radioactivity rather than its chemical properties. Once inhaled or absorbed through a wound, plutonium lodges in bone and liver for years, bathing nearby cells in alpha radiation that can trigger cancers. The story is more nuanced than the popular image of plutonium as an instant death sentence, and the route of exposure matters enormously.
Why Alpha Radiation Makes Plutonium So Harmful
Plutonium-239, the most common isotope encountered in nuclear workplaces, decays by emitting alpha particles. These are relatively heavy, energetic chunks of matter (two protons and two neutrons) that cannot penetrate the outer layer of dead skin. A sealed container of plutonium sitting on a table poses little external radiation hazard. The problem starts when plutonium gets inside the body. Alpha particles deposit all their energy along an extremely short path, roughly 45 micrometers in soft tissue, which is about the width of a single human hair. That means all the damage concentrates in cells immediately surrounding the plutonium deposit rather than spreading across a large volume.
This concentrated energy dump is far more biologically destructive per unit of dose than the same energy delivered by X-rays or gamma rays. Studies using plutonium-238 alpha sources on blood-forming stem cells found that alpha particle exposure produced a high frequency of chromosomal abnormalities not just in the directly hit cells but in their descendants. Cells that were never directly irradiated inherited unstable chromosomes from their parent cells, a phenomenon called genomic instability. X-rays at comparable doses did not produce this effect. That inherited instability is one reason alpha-emitting radionuclides inside the body are considered especially dangerous for cancer induction.
How Plutonium Enters the Body
Four routes can deliver plutonium past the skin barrier, but they are not equally important. Inhalation is by far the most significant occupational hazard. Microscopic plutonium particles lodge deep in the lungs, and the body’s response creates a long-term problem: scar tissue forms around the particles and traps them. Modeling of both animal experiments and human case data indicates that scar-tissue retention accounts for roughly 30 to 90 percent of all plutonium activity remaining in the respiratory tract, depending on the chemical form inhaled.1PubMed. Mechanisms for Long-term Retention of Plutonium in the Respiratory Tract: Inferences from Animal and Human Studies Soluble forms are gradually absorbed into the bloodstream and carried elsewhere; insoluble oxides can stay trapped in lung tissue for decades.
Contaminated wounds are the second most concerning route. Nuclear fuel workers and reactor decommissioning staff occasionally receive puncture wounds or cuts contaminated with plutonium or americium.2PubMed Central. Decontamination of Actinide-contaminated Injured Skin with Ca-DTPA Products Using an Ex Vivo Rat Skin Model Plutonium entering through a wound can reach the bloodstream rapidly, bypassing the lung’s partial filtration. In animal studies, surgical excision of the wound site days after contamination released additional plutonium into urine but did not increase long-term organ deposits, suggesting the body had already begun redistributing the material.3PubMed. Combined drug and surgery treatment of plutonium-contaminated wounds: indications obtained using a rodent model
Ingestion, surprisingly, is a much less efficient entry route, as discussed in the next section. Intact skin absorption is the least significant pathway, though injured skin allows considerably greater penetration.
Swallowing Plutonium Is Less Dangerous Than You’d Think
One of the most persistent misconceptions about plutonium is that even a tiny amount swallowed will kill you. In reality, the gut is remarkably bad at absorbing it. Studies in hamsters and other animals put the absorption fraction for soluble plutonium at about 0.01 percent of the amount swallowed, and for the dioxide form it drops to roughly 0.0001 percent.4PubMed. The gastrointestinal absorption of plutonium and americium in the hamster That means if you somehow swallowed plutonium in its most common oxide form, only about one millionth of the material would actually reach your bloodstream. The rest passes through and is excreted.
Chemical form and concentration do matter to some degree. Mouse experiments showed that at higher concentrations, plutonium citrate was absorbed more readily than nitrate, though at low concentrations the chemical form mattered less.5PubMed. The effect of mass on the gastrointestinal absorption of plutonium and neptunium Age is a bigger factor: newborn animals absorbed plutonium through the gut at rates ten to a hundred times higher than adults, reflecting the more permeable intestinal lining of neonates.5PubMed. The effect of mass on the gastrointestinal absorption of plutonium and neptunium This is worth noting because it means the standard adult absorption estimates would underestimate risk to infants.
None of this makes swallowing plutonium safe. Even the tiny fraction that reaches the bloodstream can deposit in bone and liver, and alpha radiation from long-lived isotopes delivers damage over years. But pound for pound, inhaling the same quantity is orders of magnitude more dangerous than swallowing it.
Where Plutonium Settles Inside the Body
Once plutonium enters the bloodstream, it does not distribute evenly. It behaves somewhat like iron in the body, binding to the iron-transport protein transferrin and being carried to specific organs. Analysis of data from over 250 experimental animals and 169 human cases led researchers to conclude that about 70 percent of the plutonium in the body deposits in the skeleton and about 30 percent goes to the liver.6PubMed. Plutonium partitioning among internal organs All other organs and early excretion combined account for less than 3 percent of the total burden.
Within the skeleton, the picture gets more specific. Postmortem analysis of whole-body donations to the United States Transuranium Registry found that plutonium concentrates on bone surfaces, particularly the periosteum (outer lining) and endosteum (inner lining), rather than distributing throughout the bone marrow. Less than 5 percent of the skeletal plutonium was found in the marrow itself.7Journal of Radioanalytical and Nuclear Chemistry. Implications of postmortem human tissue analysis on biokinetic models for actinides That surface localization is critical because the cells most vulnerable to alpha-particle-induced cancer (bone-lining cells) sit right on those surfaces, within the 45-micrometer range of plutonium’s alpha emissions.8PubMed Central. Review of the anatomical basis for predicting plutonium alpha particle radiation induced osteogenic cancers
These same postmortem studies also found a measurable fraction of plutonium retained in muscle tissue, something not predicted by earlier models.7Journal of Radioanalytical and Nuclear Chemistry. Implications of postmortem human tissue analysis on biokinetic models for actinides The retention in bone and liver appears to last years, with biological half-times measured in decades rather than months.
Cancer Risk from Occupational Plutonium Exposure
The strongest human evidence for plutonium’s cancer-causing effects comes from workers at the Mayak Production Association in Russia, where nuclear weapons were manufactured under conditions that often exposed workers to significant internal plutonium doses. A pooled analysis combining the Mayak cohort with workers from the Sellafield facility in the United Kingdom — together totaling nearly 46,000 workers — found clear evidence of a linear relationship between cumulative plutonium lung dose and lung cancer risk. Among men at age 60, the excess relative risk was in the range of 5 to 8 per gray of plutonium lung dose for both lung cancer deaths and new diagnoses.9PubMed. Lung Cancer Risk from Plutonium: A Pooled Analysis of the Mayak and Sellafield Worker Cohorts A separate analysis of nuclear workers in multiple countries found an even steeper dose-response specifically for plutonium, with an excess odds ratio of about 50 per gray after adjusting for external radiation, smoking, and socioeconomic status.10PubMed Central. Risk of Lung Cancer Mortality in Nuclear Workers from Internal Exposure to Alpha Particle-emitting Radionuclides The difference between these two estimates reflects differences in study design, dose assessment methods, and the populations analyzed, but both point in the same direction: plutonium in the lungs is a potent carcinogen.
Liver cancer tells a similar story. Among Mayak workers with estimated plutonium body burdens above 7.4 kilobecquerels, the relative risk of liver cancer was about 17 times that of workers without detectable burdens.11Radiation Research. Liver Cancers in Mayak Workers The dominant type of liver cancer associated with plutonium was hepatocellular carcinoma, the same type most commonly seen in viral hepatitis and alcohol-related liver disease. At very high internal doses (above 4 gray to the liver), a rarer tumor type called hemangiosarcoma appeared — a cancer of blood vessel lining cells that is virtually nonexistent in the general population and strongly associated with specific toxic exposures.12PubMed. Radiation risk of malignant neoplasms in organs of main deposition for plutonium in the cohort of Mayak workers with regard to histological types A more recent analysis of Mayak workers estimated the excess relative risk of liver malignancy at about 7.6 per gray of alpha dose from internal exposure.13Scientific Reports. Incidence risk of hepatobiliary malignant neoplasms in the cohort of workers chronically exposed to ionizing radiation
Bone cancer is harder to quantify in humans because it is rarer to begin with, but animal studies consistently show that plutonium deposited on bone surfaces causes osteosarcoma. Comparative work across the actinide elements found that the efficiency of bone cancer induction per unit of radiation dose may vary with the element: neptunium appeared somewhat more effective than plutonium, which in turn was more effective than americium, likely due to microscopic differences in where each element deposits on bone surfaces.14PubMed. The biodistribution and toxicity of plutonium, americium and neptunium
Treatment After Plutonium Contamination
The primary medical treatment for internal plutonium contamination is chelation therapy with a compound called DTPA (diethylenetriaminepentaacetic acid). DTPA binds to plutonium in the blood and tissues, forming a complex that the kidneys can filter out and excrete in urine. Speed matters: the sooner treatment begins after exposure, the more plutonium can be intercepted before it locks into bone and liver.
Research in rats has shown that inhaling a nebulized DTPA solution directly into the lungs can be more effective at clearing lung plutonium than an intravenous injection, even at a much lower dose. A single inhalation at about 1.1 micromoles per kilogram outperformed a single intravenous dose nearly fourteen times larger at removing the transportable fraction of plutonium from the lungs. The inhaled DTPA caught the plutonium before it entered the bloodstream, preventing deposition in liver and bone. Intravenous DTPA, on the other hand, was better at reducing plutonium that had already spread to other organs.15PubMed. Chelation Treatment by Early Inhalation of Liquid Aerosol DTPA for Removing Plutonium after Rat Lung Contamination The researchers concluded that combining both routes — prompt inhalation plus intravenous injection — produced the best results, and that repeated inhaled treatments over several weeks continued to trap freshly mobilized plutonium.
Even when treatment is delayed, DTPA retains some usefulness. Modeling of a real human case involving plutonium-238 inhalation treated with delayed chelation therapy suggested that the drug can reach plutonium already taken up inside cells, not just material circulating freely in the blood.16Radiation Research. Chelation Modeling of a Plutonium-238 Inhalation Incident Treated with Delayed DTPA For contaminated wounds, the approach typically combines surgical removal of affected tissue with DTPA to catch any plutonium that has already migrated away from the wound site.3PubMed. Combined drug and surgery treatment of plutonium-contaminated wounds: indications obtained using a rodent model
Differences Between Plutonium Isotopes
Not all plutonium isotopes behave identically in the body. Plutonium-239 (the weapons-grade isotope, with a half-life of about 24,000 years) and plutonium-238 (used in space probe power sources, with a half-life of about 88 years) are both alpha emitters, but gram for gram, Pu-238 is far more radioactive because it decays much faster. You might expect that to make Pu-238 more dangerous inside a cell, but laboratory experiments told a more complicated story. When cells were exposed to equal amounts of each isotope, Pu-239 actually caused more cell death. The reason appears to be cellular handling: both isotopes were taken up at similar rates, but Pu-238 was cleared from cells more quickly and distributed differently within subcellular compartments.17PubMed. Differences in the radiotoxicity of two plutonium isotopes in cells in vitro: can they be ascribed to different handling by the cells? The practical upshot is that simple activity-per-gram comparisons can be misleading; where the isotope parks itself inside the cell changes how much damage it actually does.
Among the broader actinide family, plutonium, americium, and neptunium share remarkably similar biochemical behavior despite having different solution chemistry. All three bind to the same blood transport proteins, concentrate in liver and skeleton, and cause cancers in the same organs. The cancer risk per unit dose to the liver appears similar across the three elements.14PubMed. The biodistribution and toxicity of plutonium, americium and neptunium The differences show up mainly in bone, where the microscopic distribution of each element near bone-lining cells varies enough to change the cancer induction efficiency.
Plutonium Transfer to the Fetus
One question rarely discussed in popular accounts is whether plutonium can cross the placenta. It can. In baboons given an intravenous injection of a mixture of actinide elements during the fifth month of pregnancy, about 4 percent of the administered plutonium-239 was found in the fetus one week later. The placenta itself retained 8 to 12 percent. These levels were strikingly higher than for americium (only 0.4 percent reached the fetus) and were even higher than polonium or neptunium.18Radiation Protection Dosimetry. Transfer of polonium, neptunium, plutonium and americium to the primate fetus The fetal-to-maternal concentration ratio for plutonium was about 1.3, meaning the fetal tissues were actually more concentrated than the mother’s on a per-gram basis.
Mouse studies found broadly similar patterns, though the absolute levels of fetal transfer were generally lower than in primates. One finding from the mouse work is that the fraction of dose reaching the fetus decreased as the dose to the mother increased, suggesting that low-dose data cannot simply be scaled up from high-dose experiments.19Health Physics. PLACENTAL TRANSFER OF AMERICIUM AND PLUTONIUM IN MICE The researchers recommended that estimates of dose to human fetuses during the third trimester be based on the baboon data, since the primate placenta more closely resembles the human one. These findings underscore why occupational exposure limits for pregnant workers in the nuclear industry are set considerably lower than for the general workforce.
Environmental Plutonium and Everyday Risk
Nearly everyone alive today carries a tiny amount of plutonium in their body, a legacy of atmospheric nuclear weapons testing in the 1950s and 1960s, with additional contributions from the Chernobyl accident. Estimating these body burdens requires accounting for both global fallout and regional contamination sources.20Journal of Radioanalytical and Nuclear Chemistry. Evaluation of the Plutonium Content in the Human Body Due to Global and Chernobyl Fallout The amounts involved are vanishingly small, typically measured in millibecquerels, and deliver radiation doses far below those associated with measurable cancer risk in the worker studies.
Plutonium in soil generally binds tightly to minerals and organic matter, making it relatively immobile. Its availability for uptake into food crops depends heavily on soil acidity and chemical conditions. Research on potato plants grown in plutonium-contaminated solution found that the element’s solubility and plant availability were governed primarily by pH and the redox potential of the soil water.21PubMed. Uptake of Plutonium-238 into Solanum tuberosum L. (potato plants) in presence of complexing agent EDTA Under normal agricultural conditions, very little plutonium moves from soil into the food chain. The scenarios where environmental plutonium poses a genuine public health concern are highly localized: areas immediately surrounding former weapons production facilities, nuclear test sites, and severe accident zones where resuspension of contaminated dust could lead to inhalation.
Detecting internal plutonium contamination at these low environmental levels is technically challenging. Modern bioassay programs rely on collecting urine or fecal samples and using advanced radiochemical separation techniques combined with mass spectrometry to measure trace and ultratrace levels of actinides.22Health Physics. An Overview of Analytical Methods for in Vitro Bioassay of Actinides These methods are sensitive enough to detect occupational exposures well below the threshold where health effects would be expected, but they require specialized laboratories and are not something a standard blood test can accomplish.